Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals (ARMP) Capital Expenditures (2016 - 2018)

Armata Pharmaceuticals (ARMP) has disclosed Capital Expenditures for 6 consecutive years, with $391000.0 as the latest value for Q4 2018.

  • Quarterly Capital Expenditures rose 2072.22% to $391000.0 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $597000.0 through Dec 2018, up 929.31% year-over-year, with the annual reading at $542000.0 for FY2025, 71.15% down from the prior year.
  • Capital Expenditures hit $391000.0 in Q4 2018 for Armata Pharmaceuticals, up from $155000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $831000.0 in Q2 2014 to a low of $2000.0 in Q2 2017.
  • Historically, Capital Expenditures has averaged $127500.0 across 5 years, with a median of $42500.0 in 2015.
  • Biggest five-year swings in Capital Expenditures: tumbled 98.92% in 2015 and later surged 2072.22% in 2018.
  • Year by year, Capital Expenditures stood at $5000.0 in 2014, then surged by 900.0% to $50000.0 in 2015, then plummeted by 74.0% to $13000.0 in 2016, then surged by 38.46% to $18000.0 in 2017, then soared by 2072.22% to $391000.0 in 2018.
  • Business Quant data shows Capital Expenditures for ARMP at $391000.0 in Q4 2018, $155000.0 in Q3 2018, and $18000.0 in Q4 2017.